Omega Therapeutics Net Worth
Omega Therapeutics Net Worth Breakdown | OMGA |
Omega Therapeutics Net Worth Analysis
Omega Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Omega Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Omega Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Omega Therapeutics' net worth analysis. One common approach is to calculate Omega Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Omega Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Omega Therapeutics' net worth. This approach calculates the present value of Omega Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Omega Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Omega Therapeutics' net worth. This involves comparing Omega Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Omega Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Omega Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Omega Therapeutics' net worth research are outlined below:
| Omega Therapeutics generated a negative expected return over the last 90 days | |
| Omega Therapeutics has high historical volatility and very poor performance | |
| Omega Therapeutics has some characteristics of a very speculative penny stock | |
| Omega Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 3.09 M. Net Loss for the year was (97.43 M) with loss before overhead, payroll, taxes, and interest of (74.02 M). | |
| Omega Therapeutics currently holds about 173.66 M in cash with (91.51 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.63, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Omega Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 90.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Omega Therapeutics, Inc. Reports Q3 Loss, Tops Revenue Estimates - MSN |
Omega Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Omega Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Omega Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 6th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 6th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Omega Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Omega Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Omega Therapeutics backward and forwards among themselves. Omega Therapeutics' institutional investor refers to the entity that pools money to purchase Omega Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | 72 Investment Holdings, Llc | 2024-09-30 | 352.9 K | Junked Platinum Investment Management Ltd | 2024-09-30 | 346.4 K | State Treasurer State Of Michigan | 2024-09-30 | 314.1 K | Geode Capital Management, Llc | 2024-09-30 | 230.8 K | Squarepoint Ops Llc | 2024-06-30 | 222.4 K | Jane Street Group Llc | 2024-06-30 | 213.5 K | Goldman Sachs Group Inc | 2024-06-30 | 190.1 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 188 K | Bridgeway Capital Management, Llc | 2024-09-30 | 119 K | Flagship Ventures Management, Inc. | 2024-06-30 | 29.2 M | Fmr Inc | 2024-09-30 | 6.1 M |
Follow Omega Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 43.52 M.Market Cap |
|
Project Omega Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.48) | (0.50) | |
| Return On Capital Employed | (0.56) | (0.59) | |
| Return On Assets | (0.48) | (0.50) | |
| Return On Equity | (1.68) | (1.60) |
When accessing Omega Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Omega Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Omega Therapeutics' profitability and make more informed investment decisions.
Please note, the presentation of Omega Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Omega Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Omega Therapeutics' management manipulating its earnings.
Evaluate Omega Therapeutics' management efficiency
Omega Therapeutics has return on total asset (ROA) of (0.2537) % which means that it has lost $0.2537 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2915) %, meaning that it created substantial loss on money invested by shareholders. Omega Therapeutics' management efficiency ratios could be used to measure how well Omega Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 26, 2024, Return On Tangible Assets is expected to decline to -0.5. In addition to that, Return On Capital Employed is expected to decline to -0.59. At present, Omega Therapeutics' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 120.2 M, whereas Total Assets are forecasted to decline to about 135.9 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.07 | 0.86 | |
| Tangible Book Value Per Share | 1.07 | 0.86 | |
| Enterprise Value Over EBITDA | (2.38) | (2.50) | |
| Price Book Value Ratio | 2.80 | 2.94 | |
| Enterprise Value Multiple | (2.38) | (2.50) | |
| Price Fair Value | 2.80 | 2.94 | |
| Enterprise Value | 222.6 M | 301.7 M |
At Omega Therapeutics, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Enterprise Value Revenue 17.452 | Revenue 6.3 M | Quarterly Revenue Growth 1.812 | Revenue Per Share 0.114 | Return On Equity (1.29) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Omega Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Omega Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Omega Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Omega Therapeutics time-series forecasting models is one of many Omega Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Omega Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Omega Therapeutics Earnings per Share Projection vs Actual
Omega Therapeutics Corporate Management
| JD Esq | Chief Secretary | Profile | |
| Kevin McManus | Chief Officer | Profile | |
| Kaan Certel | Chief Officer | Profile | |
| Barbara Chan | Principal Office | Profile | |
| Noubar Afeyan | CoFounder Chairman | Profile | |
| Jennifer Nelson | Senior Research | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Omega Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For information on how to trade Omega Stock refer to our How to Trade Omega Stock guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Omega Therapeutics. If investors know Omega will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Omega Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.32) | Revenue Per Share 0.114 | Quarterly Revenue Growth 1.812 | Return On Assets (0.25) | Return On Equity (1.29) |
The market value of Omega Therapeutics is measured differently than its book value, which is the value of Omega that is recorded on the company's balance sheet. Investors also form their own opinion of Omega Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Omega Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Omega Therapeutics' market value can be influenced by many factors that don't directly affect Omega Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Omega Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Omega Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Omega Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.